Fig. 1: Clinical efficacy of Aza + HAG regimen. | Blood Cancer Journal

Fig. 1: Clinical efficacy of Aza + HAG regimen.

From: High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study

Fig. 1

A CR/CRi rate of Aza+HAG regimen according to different disease types (newly diagnosed AML, relapsed/refractory AML, de novo AML, and secondary AML). B CR/CRi rate of Aza+HAG regimen of newly diagnosed AML patients according to different risk groups (favorable, intermediate, poor risk [ELN2017]). C, D OS (C) and RFS (D) curves of Aza+HAG regimen according to disease type. E, F OS (E) and RFS (F) curves of Aza+HAG regimen of newly diagnosed AML patients according to different risk groups. (G) CR/CRi rate of enrolled patients receiving Aza+HAG regimen versus HAG control. Patients from both the Aza+HAG and HAG control were derived from the same clinical institute (Zhongda Hospital, Nanjing, China), (H, I) OS (H) and RFS (I) curves of patients receiving the Aza+HAG regimen versus HAG control, (J) CR/CRi rate of Aza+HAG regimen were compared with previously reported CR/CRi rate of HAG regimen (data were derived from 17 studies, including 453 patients).

Back to article page